Department of Obstetrics and Gynaecology and British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, UK.
BJOG. 2022 Oct;129(11):1833-1843. doi: 10.1111/1471-0528.17222. Epub 2022 Jun 28.
Calcium supplementation reduces the risk of pre-eclampsia, but questions remain about the dosage to prescribe and who would benefit most.
To evaluate the effectiveness of high (≥1 g/day) and low (<1 g/day) calcium dosing for pre-eclampsia prevention, according to baseline dietary calcium, pre-eclampsia risk and co-interventions, and intervention timing.
CENTRAL, PubMed, Global Index Medicus and CINAHL, from inception to 2 February 2021, clinical trial registries, reference lists and expert input (CRD42018111239).
Randomised controlled trials of calcium supplementation for pre-eclampsia prevention, for women before or during pregnancy. Network meta-analysis (NMA) also included trials of different calcium doses.
Two independent reviewers extracted published data. The meta-analysis employed random-effects models and the NMA, a Bayesian random-effects model, to obtain direct and indirect effect estimates.
The meta-analysis included 30 trials (N = 20 445 women), and the NMA to evaluate calcium dosage included 25 trials (N = 15 038). Calcium supplementation prevented pre-eclampsia similarly with a high dose (RR 0.49, 95% CI 0.36-0.66) or a low dose (RR 0.49, 95% CI 0.36-0.65). By NMA, high-dose (vs low-dose) calcium did not differ in effect (RR 0.79, 95% CI 0.43-1.40). Calcium was similarly effective regardless of baseline pre-eclampsia risk, vitamin D co-administration or timing of calcium initiation, but calcium was ineffective among women with adequate average baseline calcium intake.
Low- and high-dose calcium supplementation are effective for pre-eclampsia prevention in women with low calcium intake. This has implications for population-level implementation where dietary calcium is low, and targeted implementation where average intake is adequate.
A network meta-analysis of 25 trials found that low-dose calcium supplementation (<1 g/day) is as effective as high-dose calcium supplementation (≥1 g/day) in halving the risk of pre-eclampsia when baseline calcium intake is low.
钙补充剂可降低子痫前期的风险,但关于剂量的规定和谁能最大程度获益仍存在疑问。
评估根据基线膳食钙、子痫前期风险和联合干预措施以及干预时机,高(≥1 g/天)和低(<1 g/天)剂量的钙用于子痫前期预防的效果。
CENTRAL、PubMed、全球索引医学和 CINAHL,从建库到 2021 年 2 月 2 日,临床试验注册处,参考文献列表和专家意见(CRD42018111239)。
钙补充剂预防子痫前期的随机对照试验,针对妊娠前或妊娠期间的女性。网络荟萃分析(NMA)还包括不同剂量的钙试验。
两名独立审查员提取已发表的数据。荟萃分析采用随机效应模型,NMA 采用贝叶斯随机效应模型,以获得直接和间接效果估计。
荟萃分析纳入了 30 项试验(N=20445 名女性),NMA 评估钙剂量纳入了 25 项试验(N=15038 名女性)。钙补充剂以高剂量(RR 0.49,95%CI 0.36-0.66)或低剂量(RR 0.49,95%CI 0.36-0.65)同样有效地预防子痫前期。通过 NMA,高剂量(vs 低剂量)钙在效果上没有差异(RR 0.79,95%CI 0.43-1.40)。无论基线子痫前期风险、维生素 D 联合用药或钙起始时间如何,钙的效果相似,但在基线平均钙摄入量充足的女性中,钙无效。
低剂量和高剂量钙补充剂对低钙摄入女性的子痫前期预防均有效。这对低膳食钙人群的人群水平实施和平均摄入量充足的针对性实施具有重要意义。
一项对 25 项试验的网络荟萃分析发现,当基线钙摄入量较低时,低剂量钙补充剂(<1 g/天)与高剂量钙补充剂(≥1 g/天)同样有效,可将子痫前期的风险减半。